|Day's Range||132.88 - 136.97|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-237.23|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.
Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY). Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion. Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed.